PROLONGED SURVIVAL IN HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS (PTS) WITH-7/DEL(7Q) TREATED WITH AZACITIDINE (AZA)

被引：0
|
作者：
Mufti, G. J. [1 ]
Garcia-Manero, G. [2 ]
Hovarth, N. [3 ]
Lim, Z. [4 ]
Quesnel, B. [5 ]
Leone, G. [6 ]
Bennett, J. [7 ]
Sanz, G. [8 ]
McKenzie, D. [9 ]
Backstrom, J. [9 ]
Beach, C. L. [9 ]
机构：
[1] Kings Coll Hosp London, London, England
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] IMVS, Adelaide, SA, Australia
[4] Kings Coll London, London WC2R 2LS, England
[5] CHU Lille, Serv Malad Sang, F-59037 Lille, France
[6] Policlin Gemelli, Div Ematol, Rome, Italy
[7] Univ Rochester, Rochester, NY 14627 USA
[8] Hosp Univ La Fe, Inst Name, Valencia, Spain
[9] Pharm Corp, Overland Pk, KS USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0928
引用
收藏
页码：369 / 370
页数：2
相关论文
共 50 条
  • [31] Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
    Diez-Campelo, Maria
    Lorenzo, Jose I.
    Itzykson, Raphael
    Rojas, Silvia M.
    Berthon, Celine
    Luno, Elisa
    Beyne-Rauzy, Odile
    Perez-Oteyza, Jaime
    Vey, Norbert
    Bargay, Joan
    Park, Sophie
    Cedena, Teresa
    Bordessoule, Dominique
    Munoz, Juan A.
    Gyan, Emmanuel
    Such, Esperanza
    Visanica, Sorin
    Lopez-Cadenas, Felix
    de Botton, Stephane
    Hernandez-Rivas, Jesus M.
    Ame, Shanti
    Stamatoullas, Aspasia
    Delaunay, Jacques
    Salanoubat, Celia
    Isnard, Francoise
    Guieze, Romain
    Perez Guallar, Joan
    Badiella, Llorenc
    Sanz, Guillermo
    Canizo, Consuelo
    Fenaux, Pierre
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (03) : 350 - 359
  • [32] Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk.
    Gattermann, Norbert
    Sanz, Guillermo F.
    Giagounidis, Aristoteles
    Seymour, John F.
    Fenaux, Pierre
    Santini, Valeria
    Mufti, Ghulam J.
    Muus, Petra
    Ramos, Fernando
    Lucy, Lela M.
    Beach, C. L.
    Silverman, Lewis R.
    BLOOD, 2010, 116 (21) : 1643 - 1644
  • [33] The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study
    Garcia, Jacqueline S.
    Wei, Andrew H.
    Borate, Uma
    Fong, Chun Yew
    Baer, Maria R.
    Nolte, Florian
    Peterlin, Pierre
    Jurcic, Joseph
    Jacoby, Meagan
    Hong, Wen-Jen
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Cunningham, Ilona
    Zhou, Ying
    Dunbar, Martin
    Harb, Jason G.
    Popovic, Relja
    Tanwani, Poonam
    Gopalakrishnan, Sathej
    Wolff, Johannes
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S315 - S316
  • [34] Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
    Zeidan, Amer M.
    Gore, Steven D.
    Komrokji, Rami S.
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (03) : 251 - 254
  • [35] A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial.
    Itzykson, Raphael
    Thepot, Sylvain
    Quesnel, Bruno
    Dreyfus, Francois
    Beyne-Rauzy, Odile
    Turlure, Pascal
    Recher, Christian
    Dartigeas, Caroline
    Vey, Norbert
    Legros, Laurence
    Delaunay, Jacques
    Salanoubat, Celia
    Visanica, Sorin
    Stamatoullas, Aspasia
    Isnard, Francoise
    Marfaing-Koka, Anne
    De Botton, Stephane
    Chelgoum, Youcef
    Taksin, Anne-Laure
    Plantier, Isabelle
    Ame, Shanti
    Boehrer, Simone
    Gardin, Claude
    Beach, C. L.
    Ades, Lionel
    Fenaux, Pierre
    BLOOD, 2010, 116 (21) : 1628 - 1629
  • [36] Effectiveness of Azacitidine in Frontline Higher-Risk Myelodysplastic Syndrome: A Retrospective Cohort Study of 382 Patients
    Nishathan, Rajakumaraswamy
    Mitul, Gandhi
    Andrew, H. Wei
    David, A. Sallman
    Navel, G. Daver
    Shuyuan, Mo
    Shahed, Iqbal
    Manli, Chen
    Yunfei, Wang
    Paresh, Vyas
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S15 - S15
  • [37] AZACITIDINE (AZA) IN HIGHER RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES (ABN 7): RESULTS OF A RETROSPECTIVE STUDY FROM THE GFM AND GESMD REGISTRIES
    Diez Campelo, M.
    Lorenzo, J. I.
    Itzykson, R.
    Porras, S. Rojas
    Guieze, R.
    Luno, E.
    Berthon, C.
    Hernandez Rivas, J. M.
    Beyne-Rauzy, O.
    Perez de Oteiza, J.
    Vey, N.
    Xicoy, B.
    Park, S.
    Bailen Garcia, A.
    Bordessoule, D.
    Bargay, J.
    Gyan, E.
    Such, E.
    Visanica, S.
    Cedena, T.
    De Botton, S.
    Tormo, M.
    Ame, S.
    Calabuig, M.
    Stamatoullas, A.
    Ramos, F.
    Delaunay, J.
    Guinaldo, M. A. Ruiz
    Salanoubat, C.
    Gonzalez, A. Fernandez
    Isnard, F.
    Sanz, G.
    Guieze, R.
    del Canizo, C.
    Fenaux, P.
    HAEMATOLOGICA, 2015, 100 : 240 - 240
  • [38] AZACITIDINE (AZA) IN HIGHER RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES (ABN 7): RESULTS OF A RETROSPECTIVE STUDY FROM THE GFM AND GESMD REGISTRIES
    Diez Campelo, M.
    Lorenzo, J. I.
    Itzykson, R.
    Rojas, S. M.
    Berthon, C.
    Luno, E.
    Beyne-Rauzy, O.
    Perez-Oteyza, J.
    Vey, N.
    Bargay, J.
    Park, S.
    Cedena, T.
    Bordessoule, D.
    Munoz, J. A.
    Gyan, E.
    Such, E.
    Visanica, S.
    Benlloch, L.
    de Botton, S.
    Hernandez-Rivas, J. M.
    Ame, S.
    Stamatoullas, A.
    Delaunay, J.
    Salanoubat, C.
    Isnard, F.
    Guieze, R.
    Sanz, G.
    Canizo, M. C.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2015, 39 : S107 - S107
  • [39] Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
    Amer M. Zeidan
    Maximilian Stahl
    Michelle DeVeaux
    Smith Giri
    Scott Huntington
    Nikolai Podoltsev
    Rong Wang
    Xiaomei Ma
    Amy J. Davidoff
    Steven D. Gore
    Blood Cancer Journal, 8
  • [40] Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
    Zeidan, Amer M.
    Stahl, Maximilian
    DeVeaux, Michelle
    Giri, Smith
    Huntington, Scott
    Podoltsev, Nikolai
    Wang, Rong
    Ma, Xiaomei
    Davidoff, Amy J.
    Gore, Steven D.
    BLOOD CANCER JOURNAL, 2018, 8
12345